Achievable Outcomes with Anti-CD-47 Interference and Importance of Pretreatment ABO and RH Typing

Ever since the introduction of anti-CD38 (daratumumab, or DARA), blood bankers have been hearing about a new chemotherapy agent, anti-CD47, that would interfere far more in our testing than anti-CD38. Well, anti-CD47 is here (in trials), and it lives up to its reputation! Connie Westhoff and her team report on results from blood bank testing of patients taking the drug, and what you can do to overcome the problems.

NOTE: CE credit has expired for this episode.